Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 37Nausea 25Neoplasms 12Breast Neoplasms 6Lymphoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia 2Hematologic Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms, Male 2Weight Loss 1Solid Tumors 1Sarcoma 1Radiation Injuries 1Pancreatic Neoplasms 1Pain 1Neoplasms, Germ Cell and Embryonal 1Nausea With Vomiting Chemotherapy-Induced 1Melanoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Hematologic Diseases 1Glioma 1

Interventions

Cisplatin 13Etoposide 11Paclitaxel 8Cyclophosphamide 7Carboplatin 7Ifosfamide 6etoposide phosphate 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5pembrolizumab 4fludarabine 4Sirolimus 4Bleomycin 4fludarabine phosphate 3Sunitinib 3Oxaliplatin 3Mesna 3Melphalan 3Filgrastim 3Drug Therapy 3Brentuximab Vedotin 3Bevacizumab 3Automobiles 3130-nm albumin-bound paclitaxel 3tremelimumab 2sodium thiosulfate 2ribociclib 2pralsetinib 2pegfilgrastim 2lutetium Lu 177 dotatate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × Palonosetron × Clear all
NCT03960151 2019-05-22

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Hoosier Cancer Research Network

Phase 2 Withdrawn

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡